Tagged with M

IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…

IMS Health Hungary IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from the other markets in the region? I believe none of the countries of the region is having a good time…

IMSA - Innovative Medecine South Africa Ms Beaumont, can you describe the association to our readers and its main objectives? Innovative Medicines South Africa (IMSA) represents manufacturers of research-based medicines, ie they market the products of their own research. Many of our members do have generic medicines in their product portfolio, and we believe there is…

Boehringer Ingelheim Hungary Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right after the fall of the Iron Curtain… Can you provide our readers with a better idea of the role that…

Genetic Immunity Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a little bit of background on myself. I left for Germany right after I finished university in Hungary, where I was…

Janssen Pharmaceutical Hungary Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag within the CEE region today? It is not the easiest question, as Hungary’s importance is changing from year to year.…

Cegedim Hungary Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other pharmaceutical markets in the region? I think key particularities are the many legal constraints. In July 2011, the law changed…

EGIS Romania You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through 2010 were certainly not the easiest years for pharmaceutical companies. What was the business environment like when you first came…

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…

Pharmstandard You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the company developed since the IPO? We were honored on the London Stock Exchange as the Best Newcomer of 2007, and…

Galderma Laboratories Russia You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the world. What convinced you to take this position? I would certainly not call my transition to Galderma a step down!…

IMS Romania We understand that you have been heading IMS Health in Romania for 10 years now, which has been quite a trajectory. Therefore, can you highlight the key milestones and achievements for IMS Romania in this past decade? IMS is partner of choice for industry because of its combination of data…